The overall survival (Figure 2A) and breast tumor-specific survival (Figure 2B) rates were both higher in the FGFR4-deficient TGFα transgenic mice than the FGFR4-WT TGFα transgenic mice. This evidence concerns the gene FGFR4 and breast neoplasm.